Empetus Tablets By Emcure Pharma Ltd.

Ritonavir is a selective, competitive, reversible inhibitor of HIV protease. By interfering with the formation of essential proteins and enzymes, ritonavir blocks the maturation of the virus and causes formation of non functional, immature, noninfectious virions. Ritonavir targets the HIV replication cycle after translation and before assembly. Thus, the drug is also active in chronically HIV infected cells. Ritonavir is well absorbed following oral administration, with peak plasma concentrations (Cmax) attained within 2 to 4 hours. Ritonavir is 98% to 99% bound to plasma proteins. The plasma half-life of ritonavir in adults averages 3 to 5 hours. The drug is metabolized in the liver. Ritonavir is eliminated through the urine and feces, five metabolites have been identified in urine and feces. Indication: Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-infection. Contraindications: Ritonavir is contraindicated in patients with known hypersensitivity to ritonavir or any of its ingredients. Ritonavir should not be administered concurrently with the drugs listed in Table 1 because competition for primarily CYP3A by ritonavir could result in inhibition of the metabolism of these drugs and create the potential for serious and/or life-threatening reactions such as cardiac arrhythmias, prolonged or increased sedation, and respiratory depression.